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ExacerbationAbstract Background: Asthma is one of the most common chronic diseases worldwide and has
been increasing in prevalence over the last few decades. Magnesium ion has an inhibitory action
on smooth muscle contraction, histamine release from mast cells and acetylcholine release from
cholinergic nerve terminals. Magnesium has been shown to relax bronchial smooth muscles and
inﬂuence the function of respiratory muscles. Hypomagnesemia have been associated with dimin-
ished respiratory muscle power.
Aim: To assess the serum Mg levels in bronchial asthma patients during stable and exacerbating
clinical conditions.
Subjects and methods: 60 Subjects were enrolled, 40 patients diagnosed as bronchial asthma and
20 healthy individuals as a control group. The asthmatic patients were divided into group (I)
chronic stable bronchial asthma and group (II) acute exacerbation of bronchial asthma.
Results: Serum Mg levels were signiﬁcantly lower in asthmatic patients compared with healthy
controls and signiﬁcantly lower in asthmatic patients during exacerbation compared with stable
asthmatics. There was a positive correlation between serum Mg levels and each of FEV1/FVC ratio
and FEV1.
Conclusion: Hypomagnesemia was found in patients with chronic stable asthma and also in
those with acute asthma exacerbation compared to control. Serum mg levels were signiﬁcantly
lower in asthmatic patients during exacerbations compared with stable asthmatics.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Asthma is a disorder deﬁned by its clinical, physiological and
pathological characteristics. The predominant feature of the
clinical history is episodic shortness of breath, particularly at
night, often accompanied by cough [1]. Total body magnesium
(Mg++) is about 25 g (1000 mmol). About 50% of it is in the
bones, only 1% is in the extracellular ﬂuid, and the rest is
within the cells. Mg++ has several actions on rabbitrculosis.
536 A.A. Ali et al.bronchial airways including relaxation of airway smooth mus-
cle, bronchodilation, anticholinergic effects, and stabilization
of mast cells [2]. Epidemiological evidence suggests that a
low dietary intake of magnesium is associated with impaired
lung function, bronchial hyper-reactivity, and wheezing. It
was found that a high magnesium intake is associated with
improvement in symptom score, though not in objective mea-
sures of air ﬂow or airway reactivity in stable asthmatic sub-
jects [3]. Hence, the aim of this work is to assess the serum
Mg levels in bronchial asthma patients (stable and during
exacerbations), compared to those of healthy controls.
Subjects and methods
This study was conducted at the El-Mahalla Chest Hospital
during the period from September 2013 to September 2014,
and included 40 adult patients with bronchial asthma, in addi-
tion to 20 age and sex matched healthy individuals as a control
group. Patients were divided into two groups (each of 20
patients) based on history, clinical examination and pulmonary
function test; Group (I): chronic stable bronchial asthma
patients during their regular follow up in the outpatient clinic.
Group (II): patients with acute exacerbation of bronchial
asthma. The exclusion criteria were: patients on diuretic ther-
apy, pregnancy, smoking, alcohol dependence, medical disor-
ders affecting serum magnesium levels e.g. chronic kidney
disease, diabetes mellitus, diarrhea. An informed consent and
ethical approval from Menouﬁa University Hospital Ethics
Committee were obtained from all participants before enroll-
ment then, each participant underwent; detailed history taking,
general and local chest examination, routine lab investigations
including measurement of serum Mg levels.Measurement of pulmonary functions
All participants underwent spirometric testing at the
Pulmonary Function Test Unit in the El-Mahalla Chest
Hospital using a turbine spirometer ‘‘Chest Graph HI-105,
Germany’’, based on a forced vital capacity maneuver, in which
the participants were requested to exhale the maximal volume
of air during a forced expiratory maneuver starting from a posi-
tion of full inspiration and ending at complete expiration.
Spirometric parameters compatible with airﬂow obstructionTable 1 Demographic and spirometric data and Mg levels of the s
Patients (n= 40) Cont
No. % No.
Gender
Male 32 80 15
Female 8 20 5
Age 50.65 ± 8.66 45.85
BMI 26.81 ± 4.46 26.15
FEV1/FVC ratio 52.14 ± 9.71 86.68
FEV1 50.93 ± 13.45 89.57
Serum Mg 1.55 ± 0.34 2.12
BMI, Body mass index; FEV1, Forced expiratory volume in the 1st secoare: reduced FEV1/FVC< 70% and FEV1 < 80% of the ref-
erence value. The degree of reversibility in FEV1 which indi-
cates a diagnosis of asthma is generally accepted as 12% and
200 ml from the pre-bronchodilator value [4].
Measurement of serum magnesium
Venous blood samplewithout any anticoagulantwas taken from
all participants, and then centrifugated for 10 min, the serum
was taken for analysis by ELISA. The reference range is 1.8–
2.6 mg/dl for total magnesium concentrations in adult male
blood serum and 1.9–2.5 mg/dl in adult female blood serum [5].
Statistical methodology
The data collected were tabulated and analyzed by SPSS
(statistical package for the social science software) version
20. Quantitative data were expressed as mean and standard
deviation (X + SD) and analyzed using student t-test for com-
parison of two groups of normally distributed variables.
Qualitative data were expressed as number and percentage
(No. & %) and analyzed using chi-square test. Person’s corre-
lation was used to study correlation between one qualitative
variable and one quantitative variable or two quantitative vari-
ables of not normally distributed data. All these tests were
used as tests of signiﬁcance at P< 0.05.
Results
As shown in Table 1 males constitute 80% of the patients and
75% of the control group with no statistically signiﬁcant dif-
ference between both groups regarding sex. There were no sta-
tistically signiﬁcant differences between patients and control
regarding age and BMI. FEV1/FVC ratio and FEV1 were
highly statistically lower in patients compared to control sub-
jects. Serum Mg levels were highly statistically lower in
patients compared to control subjects.
As shown in Table 2 the number of medications, number of
exacerbation/year and frequency of SABA/day were statisti-
cally higher in exacerbation compared to stable asthmatic
group.
As shown in Table 3 FEV1/FVC ratio, FEV1 were highly
statistically lower in the exacerbation group compared totudy participants.
rol (n= 20) Statistical test P value
%
75 v2 = 0.196 0.658
25
± 9.70 t= 1.944 0.057
± 4.91 t= 0.524 0.602
± 7.90 t= 13.781 <0.001*
± 12.89 t= 10.632 <0.001*
± 0.20 t= 8.010 <0.001*
nd; FVC, Forced vital capacity.
Table 2 Characteristics of the studied patients.
Stable (n= 20) Exacerbation (n= 20) Total (n= 40) v2 P value
No. % No. % No. %
Family history 7 35 11 55 18 45 1.616 0.204
Other atopic 9 45 11 55 20 50 0.400 0.527
Use of LABA 20 100 6 30 26 65 21.538 <0.001*
Use of ICS 20 100 18 90 38 95 2.105 0.147
Total medications 14 35
<3 drugs 14 70 0 0 26 65 21.538 <0.001*
P3 drugs 6 30 20 100
Duration of asthma (years) 12.25 ± 9.26 16.80 ± 8.63 – t 1.607 0.116
No. of exacerbation /year 3.85 ± 1.04 6.10 ± 1.41 t 5.742 <0.001*
Frequency of SABA/day 2.30 ± 0.47 2.95 ± 0.22 t 5.583 <0.001*
LABA, Long Acting B2 Agonist; ICS, Inhaled Corticosteroids; SABA, Short Acting B2 Agonist.
Table 3 Demographic data, spirometric values and serum Mg









No. % No. %
Gender
Male 15 75 17 85 v2 = 0.625 0.429
Female 5 25 3 15
Age 48.80 ± 8.86 52.50 ± 8.27 t= 1.365 0.180
BMI 27.30 ± 4.42 26.33 ± 4.56 t= 0.686 0.497
FEV1/
FVC ratio
56.80 ± 7.48 47.48 ± 9.58 t= 3.431 0.001*
FEV1 61.68 ± 6.78 40.18 ± 9.06 t= 8.495 <0.001*
Serum Mg 1.74 ± 0.33 1.37 ± 0.24 t= 4.103 <0.001*
BMI, Body mass index; SABA, Short Acting B2 Agonist; FEV1,
Forced expiratory volume in the 1st second; FVC, Forced vital
capacity.
Table 4 Correlation between serum Mg levels and certain




r p-value R p-value
Age 0.51 >0.05 0.48 >0.05
BMI 0.21 >0.05 0.19 >0.05
Duration of asthma/year 0.18 >0.05 0.2 >0.05
Frequency of SABA/day 0.61 >0.05 0.59 >0.05
FEV1/FVC ratio 0.74 <0.01** 0.698 <0.01**
FEV1 0.8 <0.01** 0.78 <0.01**
Number of exacerbation/
year
0.5 <0.01** 0.51 <0.01**
BMI, Body mass index;FEV1, Forced expiratory volume in the 1st
second; FVC, Forced vital capacity.
Table 5 Relationship between serum Mg levels and each of
use of LABA, use of ICS and total medications.
Serum mg T test P value
Use of LABA Yes 1.41 ± 0.25 8.08 <0.01
No 1.99 ± 0.3
Use of ICS Yes 1.65 ± 0.41 1.8 >0.05
No 1.84 ± 0.39
Total medications P3 1.41 ± 0.25 4.42 <0.01
<3 1.8 ± 0.33
LABA, Long Acting B2 Agonist; ICS, Inhaled Corticosteroids.
Serum Mg and bronchial asthma 537stable asthmatics. Serum Mg levels were highly statistically
lower in the exacerbation group compared to stable
asthmatics.
Table 4 shows that in both the stable asthmatics and exac-
erbation groups there was a positive correlation between serum
Mg levels and each of FEV1/FVC ratio, FEV1, while there was
a negative signiﬁcant correlation between the serum Mg levels
and the number of asthma exacerbations/year.
Table 5 shows a statistically signiﬁcant relation between
serum Mg levels and each of use of LABA and total number
of the used medications. There was no statistically signiﬁcant
relation between serum Mg levels and use of ICS.
Discussion
In the current study serum magnesium levels were signiﬁcantly
decreased in asthmatic patients compared with the control
ones, (p value < 0.001) and the mean of serum Mg levels in
asthmatic patients was 1.55 ± 0.34 and in control 2.12 ±
0.20 mg/dl (Table 1). This result was in agreement with thestudies done by Agin et al. [6], Alamoudi [7] Oladipo et al.
[8], which showed that serum Mg levels were signiﬁcantly
decreased in asthmatic patients compared to their controls.
Moreover, hypomagnesemia was found to be a common disor-
der in patients with chronic asthma. Although the cause of
hypomagnesemia in patients with chronic asthma was
unknown [7], it may be related to either low magnesium intake
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effect of therapy with b2- agonist, corticosteroid, and theo-
phylline [9,10].
This study showed that FEV1/FVC ratio was signiﬁcantly
decreased in patients with exacerbation than in stable asthmat-
ics, (p value = 0.001) and the mean of FEV1/FVC ratio in
stable asthmatics was 56.80 ± 7.48 and in exacerbation was
47.48 ± 9.58. Moreover, FEV1 was signiﬁcantly decreased in
patients with exacerbation than in stable asthmatics, (p
value < 0.001) and the mean of FEV1 in stable asthmatics
was 61.68 ± 6.78 and in exacerbation was 40.18 ± 9.06
(Table 3). This was in agreement with Sorkness et al. [11],
who reported that FEV1/FVC ratio showed a statistically sig-
niﬁcant decrease in patients with exacerbation than that of
stable asthmatics and the mean of FEV1/FVC ratio in stable
asthmatics was 89 ± 11.3 and in those in exacerbation was
79 ± 15.4. In addition, FEV1 was statistically decreased in
patients with exacerbation than that of stable asthmatics and
the mean of FEV1 in stable asthmatics was 84 ± 16.8 and in
exacerbation was 61 ± 22.0.
In the present study serum Mg levels were signiﬁcantly
decreased in patients with exacerbation than in stable asthmat-
ics, (p value < 0.001) and the mean serum Mg level in stable
asthmatics was 1.74 ± 0.33 and in exacerbation was
1.37 ± 0.24 (Table 3). This was in agreement with
Mohammad et al. [12], who reported that serum Mg levels
were signiﬁcantly decreased in asthmatic patients during exac-
erbations than stable asthmatics, and the mean of serum Mg
level in exacerbations was 1.12 ± 0.83 and in stable asthmatics
was 1.83 ± 0.44. As well, Alamoudi [13] reported that serum
Mg levels were found to be low in both stable asthmatics
and exacerbations and correlated signiﬁcantly with severity
of asthma (p value < 0.04). This can be explained by an asso-
ciation between magnesium deﬁciency and an increased airway
hyperreactivity. Evidence suggests that magnesium ions partic-
ipate in numerous biochemical and physiologic processes that
directly inﬂuence lung function and respiratory symptoms. The
mechanisms for effects of Mg on lung function include alter-
ation in airway smooth muscle function, immune function
and oxidative stress. Hypomagnesemia may also increase the
neuromuscular irritability, thus making a few individuals more
susceptible to the bronchial spasms. Low dietary magnesium
was also found to be associated with wheezes and impairment
of lung function in normal subjects, while magnesium supple-
mentation can reduce asthma symptoms [14–16].
In the current study there was a negative signiﬁcant corre-
lation between serum Mg levels and number of exacerbations/
year in both stable asthmatics and exacerbation group
(Table 4). This result was in agreement with Alamoudi [13]
who reported that the number of hospitalizations in chronic
asthmatics with low Mg (40%) was signiﬁcantly higher than
that found in chronic asthmatics with normal Mg (11.8%),
(p value = 0.04) and Das et al. [17], who reported that there
is statistically signiﬁcant relation between serum Mg levels
(normo or hypo) and previous and future exacerbations, (p
value = 0.019). This can be explained that low serum Mg
may increase airway hyper-reactivity, and hyper-responsive-
ness which renders chronic asthmatics with low Mg more
prone to develop bronchoconstriction and acute exacerbations
of asthma. This may occur through either increased produc-
tion of acetylcholine at cholinergic nerve endings or through
increased histamine release from mast cells, or may be throughincreased Ca ﬂux into airways smooth muscle cells. In addi-
tion, there may be other possible unknown mechanisms by
which hypomagnesaemia may cause bronchoconstriction and
consequently increase the incidence of hospitalization among
chronic asthmatics [18,19].
In this study there was negative non signiﬁcant correlation
between serum Mg levels and frequency of SABA/day in both
stable asthmatics and exacerbation group (Table 4). This result
was in agreement with Vittal et al. [14], who reported that
serum electrolytes like magnesium decreased signiﬁcantly in
patients with acute severe asthma who were on treatment with
salbutamol. The mechanism and clinical signiﬁcance of these
ﬁndings are unclear [14]. However, this was in disagreement
with Alamoudi [13] who reported that among b-agonist users,
the proportion who used it < once per day, every day, or more
than recommended, did not differ signiﬁcantly between
patients with normal Mg compared to patients with low Mg,
(p value = 0.678).
In the current study there was a statistically signiﬁcant rela-
tion between serum Mg levels and each of the use of LABA,
and use ofP3 medications and a non-signiﬁcant relation with
ICS (Table 5).This was in agreement with Das et al. [17], who
reported that there is statistically signiﬁcant relationship of
hypomagnesemia with the use of LABA, (p value = 0.003)
and with the use of P3 medications, (p value = 0.007). In
the same study Das et al. [17], showed a statistically signiﬁcant
relationship of hypomagnesemia with use of ICS, (p
value = 0.021) and explained this by increased urinary loss
of magnesium as a side-effect of therapy with corticosteroid
[9].
In conclusion hypomagnesemia was found in patients with
chronic stable asthma and also in those with acute asthma
exacerbation compared to control. Serum mg levels were sig-
niﬁcantly lower in asthmatic patients during exacerbations
compared with stable asthmatics. There was a signiﬁcant cor-
relation between hypomagnesemia and decrease in pulmonary
function tests, use of LABA and requirement of multiple med-
ications (P3).Conﬂict of interest
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[1] Global Initiative for Asthma (GINA). Global strategy for
Asthma management and prevention 2012; <http://www.
ginasthma.org>.
[2] W.H. Spivey, E.M. Skobeloff, R.M. Levin, Effect of Mg
Chloride on rabbit bronchial smooth muscle, Ann. Emerg.
Med. 19 (1990) 1107–1112.
[3] J. Hill, E.A. Mickl, S. Lewis, et al, Investigation of the effect of
short term change in dietary magnesium intake in asthma, Eur.
Respir. J. 10 (6) (1996) 2225–2229.
[4] R. Pellegrino, G. Viegi, V. Brusasco, et al, Interpretative
strategies for lung function tests, Eur. Respir. J. 26 (5) (2005)
948–968.
[5] L. Thomas, Clinical Laboratory Diagnostics 1sted Frankfurt,
TH-Books Verlagsgesellschaft, 1998, pp. 231–41.
[6] K. Agin, H. Darjani, Blood serum magnesium values in chronic
stable asthmatic patients: a case-control study, Tanaffos 4 (13)
(2005) 27–32.
Serum Mg and bronchial asthma 539[7] O.S. Alamoudi, Electrolyte disturbances in patients with
chronic, stable asthma: effect of therapy, Chest 120 (2) (2001)
431–436.
[8] O.O. Oladipo, C.C. Chukwu, M.O. Ajala, et al, Plasma
magnesium in adult asthmatics at the Lagos University
Teaching Hospital, Nigeria, East Afr. Med. J. 80 (9) (2003)
488–491.
[9] G. Rolla, C. Bucca, M. Burgiani, et al, Hypomagnesemia in
chronic obstructive lung disease: effect of therapy, Magnes.
Trace Elem. 9 (1990) 132–136.
[10] C.A. Haffner, M.J. Kendall, Metabolic effects of b2 agonists, J.
Clin. Pharm. Ther. 17 (1992) 155–164.
[11] R. Sorkness, E. Bleecker, W. Busse, Lung function in adults with
stable but severe asthma: air trapping and incomplete reversal of
obstruction with bronchodilation, J. Appl. Physiol. 104 (2)
(2008) 394–403.
[12] H.A. Mohammad, M.T. Abdulfttah, A.O. Abdulazez, et al, A
study of electrolyte disturbances in patients with chronic stable
asthma and with asthma attacks, Egypt. J. Chest Dis. Tuberc. 63
(2014) 529–534.[13] O.S. Alamoudi, Hypomagnesaemia in chronic, stable
asthmatics: prevalence, correlation with severity and
hospitalization, Eur. Respir. J. 16 (2000) 427–431.
[14] B.G. Vittal et al, A study of magnesium and other serum
electrolyte levels during nebulized salbutamol therapy, J. Clin.
Diagn. 4 (2010) 3460–3464.
[15] L. Husemoen, C. Glumer, C. Lau, et al, Association of obesity
and insulin resistance with asthma and aeroallergen
sensitization, Allergy 63 (2008) 575–582.
[16] S. Ramsay, K. Dagg, I. McKay, et al, Investigations on the
renin-angiotensin system in acute severe asthma, Eur. Respir. J.
10 (1997) 2766–2771.
[17] S.K. Das, A.K. Halder, I. Ghosh, et al, Serum magnesium and
stable asthma: Is there a link?, Lung India 27 (4) (2010) 205–208
[18] T. Gustafson, K. Boman, L. Rosenhall, et al, Skeletal muscle
magnesium and potassium in asthmatics treated with oral b2
agonists, Eur. Respir. J. 9 (1996) 237–240.
[19] A.Emelyanov,G.Fedoseev,P.J. Barnes,Reduced intracellularMg
concentration in asthmaticpatients,Eur.Respir. J. 13 (1999) 38–40.
